Lian Liu, Song Wei Su, Yong Xu, Qin Wan, Xiao Ling Yang, Yu Ying Tang and Hong Yan Sun
Background: Acarbose and voglibose are alpha-glucosidase inhibitors and they are an effective therapy in patients with diabetes mellitus. Our aim is to directly compare the efficacy and safety of acarbose and voglibose for the treatment of patients with type 2 diabetes.
Methods: We searched the international web databases (PubMed, EMBASE, Cochrane Library, Web of Science) with an English language restriction (up to August, 2016). In addition, we checked bibliographies of each included study and the latest reviews to identify additional studies. For each clinical outcome, dichotomous data were analyzed by using the risk ratio (RR) with the 95% confidence interval (CI). Continuous outcomes measured on the same scale and units were analyzed by using weighted mean differences (WMD) with the 95% confidence interval (CI); if continuous outcomes were measured on the different scale or units, it were analyzed by using standardised mean differences (SMD) with the 95% confidence interval (CI).
Results: There are no differences in glycemic control between acarbose and voglibose while adverse events in acarbose group were higher than voglibose group.
Conclusion: Our limited evidence finds that voglibose is more suitable for the treatment of type 2 diabetes compared with acarbose. Further well-designed and multicentric RCTs with larger sample are required to confirm these findings.
इस लेख का हिस्सा
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu 